Aperture
Log inStart free

Calendar

Catalyst calendar

The next 14 days, free. Subscribe for the full forward calendar with a score on every row.

Upcoming biotech catalysts with model scores
DateCompanyEventBiasP(win)Forecast moveConf.
Q4 2026windowINCYIncyte Corp$22.6BToplinePhase 3Ruxolitinib CreamHidradenitis Suppurativa
balancedAperture
Q4 2026windowINCYIncyte Corp$22.6BToplinePhase 3Ruxolitinib CreamHidradenitis Suppurativa
balancedAperture
Q4 2026windowREGNRegeneron Pharmaceuticals, Inc.$70.5BToplinePhase 3RavulizumabParoxysmal Nocturnal Hemoglobinuria
balancedAperture
Q4 2026windowSLDBSolid Biosciences Inc.$722MToplinePhase 1/2SGT-001Duchenne Muscular Dystrophy
balancedAperture
Q4 2026windowINCYIncyte Corp$22.6BToplinePhase 3PovorcitinibPrurigo Nodularis
balancedAperture
Q4 2026windowINCYIncyte Corp$22.6BToplinePhase 3PovorcitinibPrurigo Nodularis
balancedAperture
Q4 2026windowPFEPfizer Inc$161BToplinePhase 2PF-07275315Atopic Dermatitis
downside leanAperture
Q4 2026windowBIIBBiogen Inc.$33.1BToplinePhase 2/3LitifilimabSubacute Cutaneous Lupus Erythematosus
balancedAperture
Q4 2026windowAMGNAmgen Inc$224BToplinePhase 3DazodalibepSjögren's Syndrome (SS)
balancedAperture
Q4 2026windowAZNAstrazeneca plc—ToplinePhase 2DurvalumabCarcinoma, Non-Small-Cell Lung
balancedAperture
Q4 2026windowAZNAstrazeneca plc—ToplinePhase 2AZD6234Obesity/Overweight
balancedAperture
Catalyst dossier
ZYNVA

hivmab

chronic hepatitis B

Topline
57Mild upside
Bias Score 57 — Mild upside. 50 is balanced.
downsidebalancedupside
If it works+64%
If it works: +64.0% close-to-close
If it misses-77%
If it misses: -77.0% close-to-close
Weighted move
69.3%

With the scores attached

Aperture

Every row above carries a probability, a two-sided move forecast and a confidence grade — plus the full dossier behind each one. The dates stay free.

Aperture unlocks the calibrated probability and Bias Score for every event.

See pricing

Showing 11 of 11 matching events.